评估肺癌生存性别差异的预后因素:来自澳大利亚大型队列研究的发现
在澳大利亚45 and Up研究前瞻性队列中,2006-2009年招募的488例女性和642例男性肺癌患者随访至2015年12月。女性中位生存1.28年 vs 男性0.77年(男性HR=1.43,95%CI 1.25-1.64,p<0.0001)。治疗相关因素解释了一半的生存差异,调整所有主要已知预后因素后男性超额风险降低超过80%(HR=1.06,95%CI 0.96-1.18,p=0.26)。
要点
- 女性肺癌中位生存1.28年 vs 男性0.77年,男性HR=1.43(95%CI 1.25-1.64,p<0.0001)。
- 治疗相关因素解释了一半的生存性别差异,生活方式和肿瘤特征分别解释28%和26%。
- 调整所有主要已知预后因素后,男性超额风险降低超过80%(HR=1.06,95%CI 0.96-1.18,p=0.26)。
核心结论
- 该澳大利亚队列中肺癌生存的性别差异在很大程度上可由已知预后因素解释,提示有机会探索治疗偏好、选择和治疗可及性的性别差异。
研究设计与样本
- 前瞻性队列研究,基于澳大利亚45 and Up研究(2006-2009年招募),纳入新发肺癌诊断的488例女性和642例男性,随访至2015年12月。
- 预后因素来自问卷数据,并与癌症登记、医院住院记录、急诊记录及政府补贴医疗服务和处方药报销记录链接。
- 采用Cox比例风险回归估计男性 vs 女性肺癌死亡的风险比(HR)和95%置信区间(CI),分别评估单一和联合关键预后因素。
主要发现
- 女性中位生存1.28年 vs 男性0.77年,男性HR=1.43(95%CI 1.25-1.64,p<0.0001)。
- 分别评估组织学亚型、诊断时分期、接受的治疗和吸烟状态各主要预后因素亚组时,生存性别差异仍然存在。
- 多变量分析显示治疗相关因素解释了生存差异的一半,生活方式和肿瘤特征分别解释28%和26%。
- 调整所有主要已知预后因素后,男性超额风险降低超过80%(HR=1.06,95%CI 0.96-1.18,p=0.26)。
临床怎么用
- 原文结论未据此给出临床推荐,仅指出该生存性别差异在很大程度上可由已知预后因素解释,提示有机会探索治疗偏好、选择和治疗可及性的性别差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Women tend to survive a lung cancer diagnosis longer than men; however potential drivers of this sex-related disparity remain largely elusive. We quantified factors related to sex differences in lung cancer survival in a large prospective cohort in Australia. METHODS: Participants in the 45 and Up Study (recruited 2006-2009) diagnosed with incident lung cancer were followed up to December 2015. Prognostic factors were identified from questionnaire data linked with cancer registrations, hospital inpatient records, emergency department records, and reimbursement records for government-subsidized medical services and prescription medicines. Hazard ratios (HRs) and 95% confidence intervals (CIs) for lung cancer death for men versus women were estimated using Cox proportional hazard regression in relation to key prognostic factors alone and jointly. RESULTS: A total of 488 women and 642 men were diagnosed with having lung cancer. Women survived significantly longer (median 1.28 versus 0.77 y; HR for men = 1.43, 95% CI: 1.25-1.64, p < 0.0001). The survival disparity remained when each subgroup of major prognostic factors was evaluated separately, including histologic subtype, stage at diagnosis, treatment received, and smoking status. Multivariable analyses revealed that treatment-related factors explained half of the survival difference, followed by lifestyle and tumor characteristics (explaining 28%, 26%, respectively). After adjusting for all major known prognostic factors, the excess risk for men was reduced by more than 80% (HR = 1.06, 95% CI: 0.96-1.18, p = 0.26). CONCLUSIONS: The sex-related lung cancer survival disparity in this Australian cohort was largely accounted for by known prognostic factors, indicating an opportunity to explore sex differences in treatment preferences, options, and access.
引用
- Yu XQ, Yap ML, Cheng ES, et al. Evaluating Prognostic Factors for Sex Differences in Lung Cancer Survival: Findings From a Large Australian Cohort. J Thorac Oncol. 2022. PMID: 35124253. doi:10.1016/j.jtho.2022.01.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。